Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 7/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8288440 | 1.00 | SMN1; SMN2 (0.70) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL8271079 | 0.86 | HPGD (0.76) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL26789172 | 0.82 | USP2 (0.70) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL4051295 | 0.82 | SMN1; SMN2 (0.70) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL4055789 | 0.82 | SMN1; SMN2 (0.70) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL25739943 | 0.82 | SMN1; SMN2 (0.70) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL3154658 | 0.82 | USP2 (0.70) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL26789169 | 0.82 | USP2 (0.70) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL10341245 | 0.81 | SMN1; SMN2 (0.64) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL24575950 | 0.81 | HPGD (0.72) | SMN1; SMN2USP2HPGDTP53ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070281937-A1 | Ion Channel Modulators | SCION PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070203194-A1 | Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | SCION PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203194-A1 | Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | SCION PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| WO-2005087750-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281937-A1 | Ion Channel Modulators | CACNA1B, CACNA1C, TRPV1 | SMN1; SMN2 661/4885USP2 3827/4885HPGD 2634/4885 |
| US-20070203194-A1 | Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | CACNA1C, CACNA1D, CACNA1G | SMN1; SMN2 564/4885USP2 2617/4885HPGD 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.